Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
NEW YORK, May 26, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023
Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. MS affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults.
GlobalData epidemiologists expect that the number of prevalent and incident cases of MS will increase during the forecast period (2013-2023) in the 10MM. In 2013, GlobalData epidemiologists forecast that there were a total of 904,908 prevalent cases of MS in the 10MM, and by 2023 GlobalData epidemiologists forecast that the number of prevalent cases will grow to 940,413 prevalent cases. During the forecast period, India will have the highest annual growth rate (AGR) at 1.99%, Spain will have the second highest (AGR: 1.05%), and China will have the third highest (AGR: 0.93%).
GlobalData epidemiologists used country-specific sources published by peer-reviewed journals to estimate the incidence and prevalence of MS in each of the 10MM. To provide a thorough description of the MS patient population in each country, GlobalData epidemiologists segmented MS incident and prevalent cases by age and sex, both of which strongly affect the epidemiology of MS. Moreover, cases are segmented into three common sub-types: relapsing-remitting MS, primary progressive MS, and secondary progressive MS. A major strength of this analysis is that the forecast methodology was consistent across the 10MM to allow for a meaningful comparison of the patient populations in each country.
- The Multiple Sclerosis (MS) EpiCast Report provides an overview of the risk factors and comorbidities, and global and historical trends of MS in the 10 major markets (10MM) (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India). It includes a 10-year epidemiological forecast of MS prevalent and incident cases segmented by sex and age (in five-year increments beginning at 20 years and ending at =85 years) in these markets.
- The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global MS market.
- Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for MS therapeutics in each of the markets covered.
1 Table of Contents
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors 9
3.2.1 Family members of MS patients have a 1%-5% risk of developing MS 9
3.2.2 Women are twice as likely to develop MS, but men have a worse prognosis 9
3.2.3 Caucasians have a higher risk of MS than any other race/ethnicity 10
3.2.4 Protective effect of vitamin D on MS may relate to latitude and month of birth 10
3.2.5 Timing of environmental exposures affects MS risk 11
3.2.6 Exposure to smoking may increase MS risk and worsen prognosis 11
3.3 Comorbidities 12
3.3.1 Autoimmune diseases may be comorbidities of MS 12
3.3.2 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates 12
3.4 Global Trends 13
3.4.1 North America 13
3.4.2 Europe 14
3.4.3 Asia 15
3.5 Forecast Methodology 16
3.5.1 Sources Used 18
3.5.2 Sources Not Used 24
3.5.3 Forecast Assumptions and Methods 24
3.6 Epidemiological Forecast of Multiple Sclerosis (2013-2023) 34
3.6.1 Total Prevalent Cases of Multiple Sclerosis 34
3.6.2 Age-Specific Prevalent Cases of Multiple Sclerosis 36
3.6.3 Sex-Specific Prevalent Cases of Multiple Sclerosis 38
3.6.4 Total Incident Cases of Multiple Sclerosis 40
3.6.5 Age-Specific Incident Cases of Multiple Sclerosis 42
3.6.6 Sex-Specific Incident Cases of Multiple Sclerosis 44
3.6.7 Multiple Sclerosis Subtypes 46
3.7 Discussion 48
3.7.1 Epidemiological Forecast Insight 48
3.7.2 Limitations of the Analysis 49
3.7.3 Strengths of the Analysis 49
4 Appendix 50
4.1 Bibliography 50
4.2 About the Authors 57
4.2.1 Epidemiologists 57
4.2.2 Reviewers 57
4.2.3 Global Director of Epidemiology 58
4.2.4 Global Head of Healthcare 58
4.3 About GlobalData 59
4.4 About EpiCast 59
4.5 Disclaimer 60
1.1 List of Tables
Table 1: Sources of Prevalence and Incidence Data Used in the Epidemiology Forecast 17
Table 2: 10MM, Prevalent Cases of MS, Ages ?20 Years, Men and Women, N, Select Years, 2013-2023 35
Table 3: 10MM, Prevalent Cases of MS, By Age, Men and Women, N (Row %), 2013 37
Table 4: 10MM, Prevalent Cases of MS, Ages ?20 Years, By Sex, N (Row %), 2013 39
Table 5: 10MM, Incident Cases of MS, Ages ?20 Years, Men and Women, N, Select Years, 2013-2023 41
Table 6: 10MM, Incident Cases of MS, By Age, Men and Women, N (Row %), 2013 43
Table 7: 10MM, Incident Cases of MS, By Sex, N (Row %), 2013 45
1.2 List of Figures
Figure 1: 10MM, Prevalent Cases of MS, Ages ?20 Years, Men and Women, N, Select Years, 2013-2023 36
Figure 2: 10MM, Prevalent Cases of MS, By Age, Men and Women, N, 2013 38
Figure 3: 10MM, Prevalent Cases of MS, Ages ?20 Years, By Sex, N, 2013 40
Figure 4: 10MM, Incident Cases of MS, Ages ?20 Years, Men and Women, N, Select Years, 2013-2023 42
Figure 5: 10MM, Incident Cases of MS, By Age, Men and Women, N, 2013 44
Figure 6: 10MM, Incident Cases of MS, By Sex, N, 2013 46
Figure 7: 10MM, MS Subtype Distributions, %*, 2013-2023 47
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001
©2012 PR Newswire. All Rights Reserved.